Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;11(5):E142-E173.
doi: 10.5489/cuaj.4586. Epub 2017 May 9.

CUA guideline on adult overactive bladder

Jacques Corcos  1 , Mikolaj Przydacz  1 , Lysanne Campeau  1 , Gary Gray  2 , Duane Hickling  3 , Christiane Honeine  1 , Sidney B Radomski  4 , Lynn Stothers  5 , Adrian Wagg  1 , Frcp Lond  6
Affiliations

CUA guideline on adult overactive bladder

Jacques Corcos et al. Can Urol Assoc J. 2017 May.

Erratum in

  • Correction to drug name.
    [No authors listed] [No authors listed] Can Urol Assoc J. 2017 May;11(5):E250. doi: 10.5489/cuaj.4722. Epub 2017 May 9. Can Urol Assoc J. 2017. PMID: 28584565 Free PMC article.
  • Correction to author list.
    [No authors listed] [No authors listed] Can Urol Assoc J. 2017 Jul;11(7):E323. doi: 10.5489/cuaj.4775. Epub 2017 Jul 11. Can Urol Assoc J. 2017. PMID: 28761598 Free PMC article.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Corcos is an advisor for Allergan, Astellas, Pfizer; a speaker for Allergan and Duchesnay; has received payments/grants/honoraria from Astellas; and has participated in clinical trials supported by Allergan and Ipsen. Dr. Przydacz has participated in clinical trials supported by Bristol-Myers Squibb. Dr. Campeau is an advisor for Astellas and Pfizer; a speaker for Astellas, Duchesnay, and Pfizer; has received payments/grants/honoraria from Astella and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Gray is an advisor for Astellas; a speaker for Astellas, Merus, and Pfizer; has received grants/honoraria from Astellas, Merus, and Pfizer; and has participated in clinical trials supported by Biones. Dr. Hickling is an advisor for Astellas and Pfizer; a speaker for Allergan and Pfizer; has received grants/honoraria from Boston Scientific; and has participated in clinical trials supported by Astellas. Dr. Radomski is an advisor for Allergan, Astellas, Duchesnay, Lilly, Merus, and Pfizer; a speaker for Astellas, Olympus, and Pfizer; and has participated in clinical trials supported by Allergan, Astellas, and Pfizer. Dr. Wagg is an advisor for Astellas and Pfizer; has received payment/grants/honoraria from Astellas, Duchesnay, Pfizer, and SCA AB; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Stothers and Ms. Honeine report no competing personal or financial interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. University of Oxford, Graduate School in EBM and Research Methods, Centre for Evidence-Based Medicine [Internet] Oxford Centre for Evidence-based Medicine – Levels of Evidence and Grades of Recommendation. [Accessed March 23, 2017]. Published 2009; Cited December 2016. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidenc...
    1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20. https://doi.org/10.3109/9781439807217-111. - DOI - PubMed
    1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: Report from the Standardization Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78. https://doi.org/10.1002/nau.10052. - DOI - PubMed
    1. Fitzgerald MP, Brubaker L. Variability of 24-hour voiding diary variables among asymptomatic women. J Urol. 2003;169:207–9. https://doi.org/10.1016/S0022-5347(05)64069-4. - DOI - PubMed
    1. Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: Questions raised by the EPIC study. BJU Int. 2008;101:1381–7. https://doi.org/10.1111/j.1464-410X.2008.07573.x. - DOI - PubMed

LinkOut - more resources